Introduction
Lung cancer, a leading cause of cancer-related deaths worldwide, is classified into non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) (Travis et al., 1995) . SCLC is an aggressive and rapidly growing tumour with early metastasis and a mean survival time from diagnosis of only a few months (Ciombor and Rocha Lima, 2006) . Whereas NSCLC is of epithelial origin, SCLC shares morphological properties with neuroendocrine cells (Chong et al., 2006) . This observation is consistent with the expression of neuroendocrine markers in SCLC, which may be due either to its cellular origin during tumourigenesis or to a key event in cellular differentiation (Anbazhagan et al., 1999) .
Negative transcriptional regulation by the neuronrestrictive silencer factor/RE1-silencing transcription factor (NRSF/REST) is an important regulatory mechanism for neuronal development. NRSF/REST, a member of the kru¨ppel-type zinc-finger family, binds to the neuron-restrictive silencer element (NRSE/repressor element 1) and acts as a negative regulator of neuronal gene transcription. As NRSEs were identified for the rat SCG10 and other neuronal genes, NRSF was initially regarded as a master negative regulator of neurogenesis (Schoenherr and Anderson, 1995) . Indeed, the number of putative NRSF/REST-regulated genes has dramatically risen since (Bruce et al., 2004) . A recent study showed that the canonical 21-bp consensus sequence of NRSE represents a subgroup of an even larger set of NRSEs, which also contains elements compressed by 1-2 bp and those extended by 3-9 bp (Otto et al., 2007) . Using two repressor domains, the NRSF/REST protein interacts with two complexes of co-repressors, mSIN3 and CoREST. By facilitating chromatin condensation, enzymatic activities of the co-repressor complexes, including histone deacetylase, histone demethylase and histone methylase, contribute to NRSF/REST-mediated repression of target genes (Ooi and Wood, 2007) .
In contrast to NRSF/REST target gene regulation, little is known about NRSF/REST regulation itself. Sequence analyses showed that human and rat NRSF/ REST genes share 68% homology and a conserved exon-intron structure. NRSF/REST gene transcription starts with three alternatively used exons, termed 1a, 1b and 1c. Among these, exon 1a is the most abundant transcription start site, accounting for E80% of transcripts (Koenigsberger et al., 2000) . Although alternative start exons suggest more than one NRSF/ REST promoter, there was no evidence of a cell line-or tissue-specific regulation, based on luciferase analysis. In the mouse, an exon 1a promoter was identified containing TATA and CAAT boxes. For the human NRSF/REST gene regulation, functionality could not be shown given low interspecies conservation (Kojima et al., 2001) . NRSF/REST comprises several splice variants, encoding proteins with four and five zincfingers (Palm et al., 1998) . The rodent variants Rest4 and Rest5, containing five instead of nine zinc-fingers, are expressed exclusively in the brain. These splice variants possess an additional conserved exon between exons 3 and 4, leading to a premature stop codon. The expression of the human Rest4 analogue sNRSF was found to be abundant in SCLC cell lines (Coulson et al., 2000; Gurrola-Diaz et al., 2003) .
Oncogenes and tumour suppressor genes are hallmarks of tumour biology. Several oncogenes and tumour suppressor genes, like TP53 and RB, have a role in the aetiology of SCLC (Kitamura et al., 2009) . Depending on the cell type analysed, NRSF/REST either behaves like a tumour suppressor (Coulson, 2005) or like an oncogene. In neuroblastoma and medulloblastoma cell lines, NRSF/REST expression is enhanced (Palm et al., 1999; Fuller et al., 2005) . NRSF/REST and MYC overexpression induces tumour development in neuronal stem cells (Su et al., 2006) . NRSF/REST is known to be degraded by SCFbeta-TRP, in which failure to degrade NRSF/REST attenuated neuronal cell differentiation (Westbrook et al., 2008) . NRSF/REST was identified as a putative tumour suppressor in different colon and SCLC cell lines where reduced or complete loss of NRSF/REST gene expression occurred (Gurrola-Diaz et al., 2003; Neumann et al., 2004; Westbrook et al., 2005) . In colon cancer, loss of NRSF/REST expression was due to a frameshift mutation, which resulted in protein truncation (Westbrook et al., 2005) . As a result of NRSF/REST tumour suppressor activity in human mammary epithelial cells, a gain in activated AKT was observed (Westbrook et al., 2005) . As NRSF/REST regulates the Mad2 gene, which codes for a cell cycle checkpoint protein, a NRSF/REST frameshift stable mutant resulted in genomic instability (Guardavaccaro et al., 2008) .
Importantly, the phosphoinositide 3-kinase-AKT pathway is one of the major cellular pathways for survival and proliferation (Pelicano et al., 2006) . Frequently, tumourigenesis is associated with de-regulation of transcriptional regulation. Previously, we and others found an upregulation of the glycine receptor and onconeural gene transcription in SCLC cells associated with a loss of negative regulation by NRSF/REST. In two SCLC lines, a complete loss of NRSF/REST transcription resulted in an increased expression of the neuronal markers, neural cell adhesion molecule (NCAM), L1-cell adhesion molecule (L1-CAM) and voltage-gated calcium channels (Neumann et al., 2004) . A recent study identified the SCG3 transcript as a prognostic biomarker for NRSF/REST-deficient SCLC (Moss et al., 2009) . Here, we show that NRSF/ REST-mediated cell differentiation and growth in SCLC is subject to upstream regulation by methylation, which ultimately affected the downstream AKT2 pathway. In addition, we define a promoter region comprising important functions in differential regulation of NRSF/REST.
Results

Expression analysis of NRSF/REST and target genes
Starting from the observation that low expression levels of NRSF/REST in the SCLC lines H69, H146 and H209 correlated with the expression of neuronal markers like L1-CAM, NCAM and voltage-gated calcium channels (Neumann et al., 2004) , and glycine receptor alpha 1 subunit (Gurrola-Diaz et al., 2003) , we identified additional SCLC lines that lacked expression of NRSF/REST and showed transcription of de-regulated neuronal transcripts. Ten SCLC and one NSCLC lines, a lung fibroblast cell line and normal lung tissue, were analysed for transcription patterns of NRSF/REST and putative regulated genes (Figure 1 ). In 80% of the SCLC lines (8/10) analysed, NRSF/REST expression was either not detectable or reduced using both reverse transcriptase (RT)-PCR and real-time semi-quantitative PCR methods (Figures 1a-c) . In addition, we detected the NRSF/REST splice variant sNRSF in 9/10 SCLC lines, in which it correlated with a decrease in NRSF/ REST full-length transcripts. NRSF/NRSE regulation correlated with the appearance of neuronal transcripts, including subunits of the inhibitory glycine receptor (glycine receptor alpha 1 subunit, glycine receptor beta subunit), the neuronal markers (L1-CAM and NCAM), neuroglobin, synapsin 1 and synaptophysin, all of which were increased along with a reduced NRSF/REST expression level (Figures 1a and b) . In contrast, normal lung tissue as well as a lung fibroblast cell line and an NSCLC line showed higher NRSF/REST expression, correlating with a preferential downregulation of neuronal marker genes ( Figure 1a ).
Regulation of NRSF/REST expression As 80% SCLC lines showed low or no expression of NRSF/REST and in light of its putative role as a tumour suppressor, we were interested in the reason for the loss of NRSF/REST expression. Following genomic PCR analysis of DNA from H128, an NRSF/RESTexpressing cell line, and from H69 and H146, cell lines without detectable expression of NRSF/REST, no significant differences in DNA content were seen that would suggest a loss of an allele (Supplementary Figure 1) . Testing for a possible epigenetic regulation of NRSF, we applied a prediction programme for CpG islands on the NRSF/REST gene. Three CpG islands were found and associated with all three transcriptionally confirmed alternative start exons (Figures 2a and d) . Treatment of four SCLC cell lines with the demethylating agent 5-aza-2 0 -deoxycytidine (5-aza-2 0 -dC) resulted in the induction of NRSF/REST in H69, both NRSF/REST and sNRSF induction in SW2 and CRL2195 and no further NRSF/REST increase in H128 (Figure 2a) . In 10 SCLC lines and two control cell lines, PIDF and HCC44, genomic PCR specific for methylation and absence of methylation was performed. Results showed that many of the SCLC lines were methylated within the NRSF CpGs (Figure 2b ). However, unmethylated CpGs were also detected showing that none of the regions were 100% methylated on both alleles. For example, CpG1 and two regions showed strong specific methylation patterns in four low NRSF/ REST-expressing SCLC cell lines (CRL2195, H69, OH3 and SW2) and one intermediate-expressing SCLC cell line (H446). In cell lines with higher NRSF/REST expression (H128, HCC44 and PIDF), virtually no methylation of CpG1 and CpG2 was found. Although CpG3 was generally found methylated among all cell lines, there was a trend for stronger methylation in low NRSF/REST-expressing SCLC cell lines. For further confirmation of NRSF/REST methylation, sequencing of methylation-specific DNA fragments from cell lines CRL2195, H69, H446 and OH3 revealed four methylated cytosines at CpG1 underlying the primers for methylation-specific PCR (Figure 2c ). Additional CpGs were found methylated in CRL2195, whereas other cell lines showed overall lower percentages of methylation for these positions (Figure 2c ).
Two putative promoter fragments were detected in close vicinity to the CpG islands with scores above 0.95 (scale 0.00-1.00). For functional analysis of the promoter fragments, we cloned the putative promoter fragments into the luciferase plasmid pGL3basic. All NRSF/ REST promoter containing fragments tested in H128 cells showed statistically significant increased luciferase activity, compared with the activity of the empty vector. Interestingly, the plasmids harbouring promoter fragment 1 (pf1, 1a-d), containing parts of CpG1, led to mostly a 10-fold increase in relative luciferase activity ( Figure 2d ; Supplementary Table 2 ). For H69, however, the constructs harbouring fragment pf1 led to a significant reduction of relative luciferase activity by 80% compared with the empty plasmid. Transcription factor prediction identified a putative TATA box (TCTATTCTCA), a binding site for TFIID (GGCTGGG), a CREB half-site (CRE, CGTCA) in reverse orientation and many other common transcription To assay functionality, we performed site-directed mutagenesis ( Figure 3a ) following a previously described approach (Lenz et al., 2006) . As a consequence, relative luciferase activity of the construct pf1 CREB À, harbouring a mutated CRE, was statistically significantly reduced as compared with relative luciferase activity of pf1 in the cell lines H128 and H69, and was also assessed in HEK293 (human embryonic kidney) cells ( Figure 3b ; Supplementary Table 2 ). HEK293 cells' relative luciferase activity of the construct pf1 CREB À showed the same levels as the empty plasmid, whereas in H128 relative luciferase activity of pf1 CREB À remained significantly increased compared with the empty plasmid. We observed a significant increase in NRSF/REST gene expression in H128 and HEK293 cells upon treatment with SP-cyclic AMP (cAMP), a stable activator of protein kinase A that mimics the effects of cAMP, whereas RP-cAMP, a competitive inhibitor of protein kinase A, remained without a statistically significant effect. Interestingly, in H128 cells SP-cAMP treatment mediated a 3.9-fold significant increase of NRSF/REST expression containing the CREB half binding site, and a 90-fold increase was observed for fibronectin-1 expression, a known positive control for NRSF   1M   1U   2M   2U   3M   3U   CRL2195   H69  H82  H128  H146  H209  H446  OH1  OH3  SW2  HCC44  PIDF   593 (Figure 2b ), possible explanations for NRSF expression could involve specific unmethylated CpG residues within CpG1 and CpG3, and possibly a role of differential histone modifications (acetylation/methylation) among SCLC cell lines. (d) Prediction of two NRSF/REST promoter fragments (pf, score 40.95 on a 0.00-1.00 scale) that partially overlap with the CpG islands and exon 1a. Fragments pf1,1a-d, pf2a and pf2b were analysed by luciferase assays. Fragment pf1 harbours the CREB binding site (vertical line) and many other transcription factor binding sites throughout sub-fragments pf1a-d, which most likely are responsible for increased luciferase activity as assayed below (nX10). Some transcription factors noted, which could bind to their putative binding sites found throughout pf1, include TFIID (pf1a); p300, which interacts with CREB to activate transcription (pf1a); nuclear factor-1 (NF-1), important for basal transcription activity (pf1a, 1b, 1c, 1d); activator protein-1 (AP-1) (two sites at 5 0 end of pf1, pf1b), activator protein-2 (AP-2) (pf1a, pf1b, pf1c, pf1d) and E2F (pf1b, pf1c, pf1d); multiple sites among pf sub-fragments for specificity protein (SP-1) (pf1a-3 sites, pf1b-5 sites, pf1c-22 sites, pf1d-18 sites), CTCF (pf1b-d); CAAT enhancer binding proteins C/EBPalpha (pf1c); and steroid hormone receptor binding sites, for example, glucocorticoid steroid hormone receptor (GR) (5 0 end of pf1, pf1a, pf1d) and estrogen receptor (ER) (pf1a, pf1b, pf1c). Promoter and enhancer activities in H128 were compared with activities in H69 cells. Asterisk indicates that at least one statistical test was significant. See Supplementary Table 2 for statistical analysis.
Modulation of small-cell lung cancer phenotype by NRSF/REST A Kreisler et al cAMP (Bowlus et al., 1991) with three CREB binding sites (Figures 3c and d ; Supplementary Table 2) .
NRSF/REST as a putative tumour suppressor To examine the influence of a loss of NRSF/REST expression on anchorage-independent growth, we performed NRSF/REST knockdown using two specific small interfering RNAs (siRNAs) targeting NRSF/ REST and soft agarose assays (Figure 4) . Results showed specificity of the siRNAs targeting NRSF/ REST, as in parallel a scrambled siRNA control had no significant effect on NRSF/REST expression. Following transfection with two siRNAs targeting NRSF/REST, expression was significantly downregulated at 72 h at both RNA and protein levels and was restored after 6 days ( Figure 4a ; Supplementary Table 2) . siRNAs targeting NRSF/REST in H128 cells resulted in significantly more cells growing in soft agarose after 72 h; however, no differences were noted transfecting H69 cells lacking NRSF, thus showing no off-target gene effects (Figures 4c and d) . In addition, siRNA-mediated NRSF/REST knockdown in H128 cell cultures also significantly increased cell number by twofold, showing a proliferating effect (data not shown).
Given a potential upstream regulation of NRSF/ REST expression by methylation and CREB, we investigated the cellular effects downstream of NRSF/ REST. As siRNA-mediated knockdown of NRSF/ REST correlated with increased AKT phosphorylation (Westbrook et al., 2005) , we analysed genomic sequences of AKT pathway members for the presence of NRSEs. On analysing the 3 0 untranslated region of the AKT2 gene, a putative NRSE was confirmed, 15 kb from the transcription start site (Bruce et al., 2004) . This NRSE of AKT2 (ATCAGCACCGGGGACAGCGCG) showed high similarity to the core sequence (TTCAG CACCACGGACAGCGCC) (Schoenherr and Anderson, 1995) . On comparing transcript and protein levels, we observed a trend of an inverse correlation of NRSF/ REST and AKT2 between NRSF/REST-expressing and -non-expressing SCLC lines that was not found for AKT1 and -3 (Figures 5a and b) . This inverse correlation was also shown functionally for both AKT2 (Figure 3c ). It is interesting to note that the CREB half-site in the NRSF promoter showed approximately a 3.9-fold gene induction, whereas the fibronectin-1 gene with three CREB promoter binding sites showed a 90-fold gene induction (Bowlus et al., 1991) . * indicates that one statistical test was significant. See Supplementary Table 2 for all statistical analysis.
Modulation of small-cell lung cancer phenotype by NRSF/REST
A Kreisler et al and active phosphorylated AKT (pAKT-Ser473) following a 1 h treatment with epidermal growth factor (EGF) (Figure 5c ). On analysing NRSF/REST and AKT2 transcripts in H128 cells transfected with siRNA targeting NRSF/REST, we observed that NRSF downregulation resulted in significant upregulation of AKT2 and synaptophysin, another neuronal transcript expressed at low levels in H128 (Figure 5d ). To show a direct regulatory role of NRSF/REST on AKT2, we rescued NRSF/REST expression by transfecting a cytomegalovirus NRSF cDNA construct into three SCLC cell lines. High levels of NRSF/REST gene and protein expression were observed between 2 and 5 days, but AKT2 protein levels only decreased from 4 to 5 days ( Figure 6a and data not shown). At the same time points that AKT2 levels fell, NRSF/REST rescue also showed reduction of anchorage-independent cell growth in soft agarose (Figure 6b ).
Discussion
Tumour phenotypes are influenced by both gene regulatory elements and the methylation state of the genome (Ferguson et al., 1995; Ekici et al., 2008) . It has become apparent that NRSF/REST acts as an important determinant of cell differentiation in SCLC (Coulson et al., 2000; Gurrola-Diaz et al., 2003; Neumann et al., 2004; Onganer et al., 2005) . Here, we show that cell differentiation and growth in SCLC mediated by NRSF/REST are subject to upstream regulation by methylation, which modulates downstream AKT2 signalling. The expression of neuronal genes is a phenotypic hallmark of SCLC tissue and cell lines (Coulson et al., 2000; Gurrola-Diaz et al., 2003; Neumann et al., 2004; Onganer et al., 2005; Moss et al., 2009) . In this study, we determined transcripts of various neuronal marker genes in SCLC lines and correlated expression levels with those of NRSF/REST and its splice variant sNRSF, thus extending other reports on SCLC lines with reduced NRSF/REST expression. Out of 15 SCLC lines analysed in this study or by others, only two lines showed high expression levels of NRSF/REST comparable with non-neuronal cells. Thus, the remaining cell lines represented a loss of NRSF/REST expression with neuronal transcripts increased (Coulson et al., 2000; Gurrola-Diaz et al., 2003; Neumann et al., 2004) . For example, expression levels of NCAM, synapsin 1 and, in particular, neuroglobin (Laufs et al., 2004) showed a strict inverse correlation with NRSF/REST expression, or correlated with the co-expression of sNRSF. Transcripts of glycine receptor alpha 1 subunit were detected in only two of the cell lines analysed, whereas transcription of L1-CAM and synaptophysin was less Modulation of small-cell lung cancer phenotype by NRSF/REST A Kreisler et al restrictive. In particular, the neuronally differentiated cell line H69, devoid of detectable NRSF/REST expression, expressed neuronal genes, ranging from subunits of ion channels to NCAMs and synapseassociated proteins. An almost polar differentiation status existed for H128, a 'neuro-suppressed' cell line, with rather no detectable expression of NRSE containing genes. Thus, the above observations indicate that for defined neuronal genes, the NRSF/NRSE system acts as a modulator of gene expression in SCLC lines.
On a molecular level, de-regulation of alternative splicing also occurs in tumours (Pio and Montuenga, 2009) . For example, lung cancers are reported to show abnormal expression of splice regulators as ASF/SF2, and result in an altered balance between Bcl-xL and Bcl-xS, two variants of the apoptosis regulator Bcl-x. In this investigation, the splice variant sNRSF was preferentially detected in SCLC and its appearance correlated with a reduction of the full-length transcript. The sNRSF splice variant is subject to controversial discussion (Magin et al., 2002; Gurrola-Diaz et al., 2003) , as it may even activate neuronal transcripts (Shimojo et al., 1999) . Possibly, binding of the splice variant that lacks the CoREST repressor domain does not serve all the functions described for the full-length NRSF/REST transcript (Palm et al., 1998) . Indeed, its presence might explain the abundance of neuronal transcripts in cell lines H446 and OH3, which express a subset of neuronal transcripts together with NRSF/ REST full-length transcript expression.
In addition to its role as a master regulator of the cell phenotype, NRSF/REST has been proposed to act as a tumour suppressor (Coulson, 2005; Westbrook et al., 2005) . Functional studies on tumour suppressor genes Note that there was no significant induction observed for H128 cells (protein levels were normalized to control b-actin using Image J). (d) siRNA-mediated downregulation of NRSF/REST in H128 cells led to significantly increased AKT2 and SYP gene expression levels using semi-quantitative RT-PCR (AKT2: untreated H128, n ¼ 6; siRNA treated H128, n ¼ 12; SYP: untreated H128, n ¼ 3; siRNA treated H128, n ¼ 6). Asterisk indicates that at least one statistical test was significant. See Supplementary Table 2 for statistical analysis.
Modulation of small-cell lung cancer phenotype by NRSF/REST A Kreisler et al have shown that in addition to DNA elements acting as enhancers or silencers, the methylation status of the genome is an important regulator of gene function (Ng and Gurdon, 2008) . Indeed, the NRSF/REST gene harbours three CpG islands that are subject to methylation in SCLC lines. Treatment of several neuronally differentiated cell lines with the de-methylating agent 5-aza-2 0 -dC induced NRSF/REST and sNRSF expression, consistent with methylation underlying the regulation of NRSF/REST. A comparison of SCLC lines determined that especially CpG1 and CpG2 were differentially methylated. Strong methylation of CpG1 occurred in cell lines CRL2195, H69, H446 and OH3, and in addition, CpG 2 methylation was detected in CRL2195, OH3 and SW2. Except for H446 cells, methylation correlated with either a 50% or greater reduction of NRSF/REST expression. Importantly, methylation-specific PCRs from all SCLC lines also generated amplificates specific for no methylation, indicating the presence of a least one unmethylated allele. The importance of NRSF/REST gene activity for the tumour phenotype became further apparent from anchorage-independent growth studies. Downregulation of NRSF/REST transcripts in H128 cells increased colony growth, but in contrast, colony growth decreased upon NRSF/REST rescue in cell lines lacking expression. Thus, we propose that methylation along with sNRSF induction may represent the underlying two hits for inactivating NRSF/REST, contributing to the neuronal differentiation and tumour growth, and thus strengthening the hypothesis that loss of heterozygosity results in silencing the silencer factor.
In addition, two promoter fragments of NRSF/REST were analysed, which in part overlapped with the differentially methylated CpG islands CpG1 and CpG2. The first fragment (pf1), overlapping with CpG1, exerted strong promoter and enhancer activities. In H128 cells, a luciferase plasmid harbouring pf1 yielded a 10-fold increase in relative luciferase activity, whereas an 80% luciferase reduction occurred in H69 cells. This supports the fact that fragment pf1 comprises important enhancers and silencers that, depending on the set of transcription factors expressed within a tumour, controls differential expression of NRSF. Furthermore, as H69 cells showed downregulated gene expression via the pf1 fragment in luciferase assays, this finding could also represent another mechanism silencing NRSF/REST in vivo. Although we observed in H69 cells an increasing luciferase effect of pf2a when this fragment was split from pf2b, it is possible that suppression occurs in vivo due a cooperative interaction. Taken together, the NRSF promoter appears to be differentially regulated in H128 and H69. Clones with an enhancing effect in H128 showed repression of luciferase activity in H69. However, responsible regulators still are not yet identified. Although the first promoter region has previously been characterized for human and mouse genes (Koenigsberger et al., 2000; Kojima et al., 2001) , it is becoming apparent that they have a role in regulating cell line-specific expression. Indeed, strong promoter activities of pf1 match the abundance of NRSF/REST transcripts initiating with exon 1a (Palm et al., 1998) .
Within the first NRSF/REST promoter fragment, we determined a CREB half-site, which was methylated in several cell lines. Many promoters of cAMP-responsive genes only contain a half-site TGACG sequence (Barco and Kandel, 2006) , which is essential for biological activity (Fink et al., 1988) . This same sequence found here in reverse orientation was shown to be a functional element. Indeed, in the unmethylated H128 cell line and in HEK293 cells, NRSF/REST expression was stimulated by treatment with a stable cAMP analogue (Van Haastert et al., 1984) , suggesting a positive regulation of NRSF/REST expression by CREB. In HEK293, this CREB site appeared to be a single enhancer as its mutation reduced the luciferase activity to the level of the empty plasmid. Likewise, the reporter system carrying the CREB motif was functional in the neuronally differentiated cell line H69, which is methylated in vivo. The methylated cytosine of this half-site fits was recovered (n ¼ 3). A reduction of AKT2 protein levels (AKT2 60 kDa) occurred on days 4 and 5. AKT protein levels were normalized to b-actin using Image J. AKT2 levels represent the mean fold decrease compared with controls at days 4 and 5 (control 5d is shown in the figure): H69: 4d (1.69-fold), 5d (2.73-fold); CRL2195: 4d (1.4-fold), 5d (1.92-fold); and SW2: 5d (1.9-fold). (b) Soft agarose assays shown at the 5th day post-transfection of H69, CRL2195 and SW2 SCLC cell lines with 3 mg pcNRSFwt ( þ ) or the control pcDNA3 vector (À). Bar ¼ 90 mm. A reduction of colony number (cm) and colony size (cs) in fold decrease compared with control were as follows: H69 (cn ¼ 1.9-fold; cs ¼ 1.7-fold); CRL2195 (cn ¼ 1.8-fold; cs ¼ 1.5-fold); and SW2 (cn ¼ 2.4-fold; cs ¼ 1.6-fold).
Modulation of small-cell lung cancer phenotype by NRSF/REST A Kreisler et al observations of others where the same CpG within the full palindromic CRE was described to be the subject for methylation (Smith et al., 2007) . Thus, we propose that the CREB site of the NRSF/REST promoter functions in vivo and is regulated by methylation. This might represent an important regulatory feedback mechanism, as NRSF/REST, CREB and micro-RNAs are reported to co-regulate target genes (Wu and Xie, 2006) .
Although in breast cancer the TAC1 gene coding for substance P was identified as a NRSF/REST target gene (Reddy et al., 2009) , we could identify AKT2 important for cell proliferation and survival as a target of NRSF/ REST in SCLC. An siRNA-mediated knockdown of NRSF/REST expression in H128 enhanced transcription of the AKT2 and synaptophysin genes in H128. We also determined that ATK2 protein levels were lower in the NRSF/REST-expressing SCLC cell line H128, but in contrast were higher in SCLC cell lines not expressing NRSF/REST. Furthermore, the finding that upon growth factor stimulation pAKT-Ser473 levels induced in a time-kinetic manner specifically in H69, a cell line not expressing NRSF, supports de-regulation of the AKT2 pathway in SCLC upon loss of NRSF/REST expression. NRSF/REST knockdown experiments also correlated with the activation of pAKT-Ser473 (Westbrook et al., 2005) , which could also be attributed to increased AKT2 protein levels. In gynaecological tumours, ectopic expression of AKT2 leads to metastasis (Arboleda et al., 2003) . In this study, AKT2 gene expression was increased in 7/10 SCLC cell lines analysed, potentially facilitating the metastazing potential of these tumours.
In SCLC, appearance of neuronal transcripts frequently correlated with the loss of NRSF/REST expression. The role of NRSF/REST is extending beyond its classical role as a silencer of neuronal genes. The interaction between NRSF/REST and AKT2 along with AKT phosphorylation underscores the tumour suppressor properties of NRSF/REST.
Materials and methods
Cell lines
SCLC cell lines consisting of: OH1 (Gazdar et al., 1980; Mabry et al., 1988) , OH3 (Carney et al., 1985; Griffin and Baylin, 1985; Mabry et al., 1988) and H82 from pleural effusions and SW2 from bone metastasis (Zimmermann et al., 1997) ; ATCC SCLC cell lines consisting of: H69, H128, H146, H209, CRL2195 and H446, normal lung fibroblast PIDF (Strissel et al., 2000) , kidney cell line HEK293 and the breast cancer cell line ZR751. The NSCLC cell line HCC44 is DSMZ (no.: ACC534). Lung and breast cancer cell lines were cultured according to Neumann et al. (2004) , PIDF in Dulbecco's modied Eagle's medium and HEK293 cells in minimum essential medium with identical supplements.
Cell line treatment
Cells (4 Â 10 5 ) were treated after 24 h. AKT induction. Cells were treated with 10 ng/ml human recombinant EGF (Sigma) (Westbrook et al., 2005) . Lung cell lines were transfected using liposomal transfection (Invitrogen, Karlsruhe, Germany); HEK293 cells were transfected using standard calcium phosphate.
siRNA treatment. For siRNA-mediated downregulation of NRSF/REST, 60 pmol of two siRNAs (Ambion, Darmstadt, Germany) were co-transfected, targeting exon 2 (5 0 -GCU UAUUAUGCUGGCAAAUTT-3 0 ) and 4 (5 0 -GGGAAAAG AUUACAGCAAATT-3 0 ). For assaying specificity, cells were transfected with a scrambled siRNA (neg-siRNA-Alexa488, Qiagen, Hilden, Germany, No. 1022563) at a total concentration of 120 pmol. Silencing was examined 48-72 h after transfection.
Transient transfections. For rescue of NRSF/REST expression, 3 mg of the cytomegalovirus promoter-NRSF cDNA containing expression vector pcNRSFwt (gift from Prof. Knebel-Doeberitz, University of Heidelberg, Heidelberg, Germany) and the empty control pcDNA3 vector were transfected into SCLC lines (Gurrola-Diaz et al., 2003; Neumann et al., 2004; Westbrook et al., 2005) . Expression was examined 48-120 h after transfection.
cAMP analogues. Cells were treated at final concentrations of 10-20 mM and harvested after 3 days. The fibronectin-1 gene was used as a positive cAMP-regulated control (Lee et al., 1998) .
Demethylation: 5-Aza-2 0 -dC (Sigma) treatment of cells was at 0.5 and 1.0 mM. For transcription analysis and depending on the cell line, 5-aza-2 0 -dC was applied 1 Â or 2 Â for 72 h or every 24 h for 96 h, and then cells were harvested.
Soft agarose anchorage-independent growth assays. Assays were in duplicates (Strick et al., 2007) . Cells were cotransfected with both siRNAs or with the pcNRSFwt or pcDNA3 control vectors 24 h before agarose set-up. Agarose cultures were fed every 2 days. Colony numbers were determined and colony sizes were measured using an internal microscope (bar ¼ 90 mM) (Zeiss, IM35) after 4 days for siRNA transfections and 5 days for transient transfection studies in six separate microscopic fields, including different agarose depths. In some agarose experiments, the total cell number of a colony was extrapolated using the correlation of 30 cells per 9.0 mM.
Gene expression analysis and methylation detection RNA was extracted using Peqgold RNA pure (Peqlab, Erlangen, Germany). Normal lung RNA was commercially purchased (Clontech, Saint Germain-en-Laye, France); 500 ng were used for reverse transcriptase-PCR. Oligonucleotides and real-time PCR primers (ABI, Darmstadt, Germany) are listed in Supplementary Table 1. Transcripts were analysed by semiquantitative RT-PCR, and PCR products quantified (Image J) (Rasband, 1997 (Rasband, -2009 ) and normalized first to the highest level observed in the set of samples followed by a second normalization after b-actin correction of the respective sample. Semi-quantitative real-time PCR was performed using NRSF, AKT2 and FN1 primers (ABI) (Strissel et al., 2008) . Determining expression changes upon chemical treatment or transfection with siRNA, 2-5 mg RNA were used for reverse transcription using the iScript kit (Biorad, Mu¨nchen, Germany) and cDNA was diluted 1:5 before RT-PCR.
CpG islands were identified using CpG island searcher (Takai and Jones, 2002) . DNA was extracted using a standard phenol-chloroform extraction method. Bisulphite treatment was performed with Epitect Bisufite Kit (Qiagen) using 1 mg of DNA. Primers for methylation-specific PCR were designed using MethPrimer (Li and Dahiya, 2002) . PCR products were cloned into TOPO and verified by sequencing. For statistics, a minimum of 10 clones were sequenced.
Reporter gene assay
Luciferase assays (Roche, Mannhein, Germany) were carried out in parallel with 3-4 independent transfections and
